ICAD

iCAD is our flagship partner. It is USA company that develops a series of AI-based software for mammography. The program can automatically detect breast tumors, indicating the percentage probability of pathology on the image, and also assesses the risk of developing pathology in the coming years. The program is installed and actively operating in all Clalit Health Services clinics and is currently in a pilot phase in several other clinics across Israel.

•    The ability to detect more types of cancer is 6.9% higher.
•    Reduces the need for a repeat examination by 7.2%.
•    Measures the risk level of developing a malignant tumor in the next two years.

The system detects microscopic tumors in mammography images with the highest level of accuracy and even alerts for women at risk within a two-year period (RISK measurement). The system, which is approved by the U.S. FDA and CE can also predict the likelihood of whether a malignant tumor will develop within the next two years. The results provide a high degree of certainty for patients and give doctors critical information that helps guide further diagnostic decisions. 
Dr. Ahuva Grobstein, Head of the Breast Imaging Unit at the Imaging Institute at Beilinson Hospital:"We examined the images of approximately 10,000 women using the AI system, and without a doubt, this is a game changer for the most common cancer among women in Israel. The system not only helps with early, accurate, and rapid tumor detection — it actually saves women’s lives, and that is the most important thing for us."

ProFound AI Breast Health Suite
Backed by science, clinical evidence, and proven patient outcomes; our suite of solutions – Detection, Density, and Risk — shine a spotlight on cancer, exposing its hiding place.  These clinically proven AI-powered solutions provide certainty and peace of mind, improving patient outcomes and saving more lives. ProFound AI offers concurrent-read, cancer-detection, and workflow solutions that rapidly and accurately analyzes each tomosynthesis image, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.
 

ProFound Scorecard
Automated, integrated, and easy to read – the ProFound Scorecard aids in early cancer detection, breast density assessment, and short-term risk evaluation via actionable mammographic case summary. Giving you the information needed to personalize patient care moving forward.
New features help breast imaging professionals quickly identify suspicious lesions by limiting the number of marks on each 3D view, and understand the level of suspicion related to lesions and the case through color-coded scoring ranges.
Includes: Overall Case Score. Automated Density Assessment Score. Personalized 1-2 year Risk Score.*
Worklist prioritization and color based on PACS viewer and output requirements.
ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use.
 

ProFound AI RISK. 
Available for 2D and 3D mammography, ProFound AI® Risk is the world’s first clinical decision support tool that provides an accurate short-term, breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram.1,2
The easy-to-implement solution provides superior insights1,2 that empower clinicians to tailor a woman’s breast healthcare follow-up and potentially identify cancers earlier. ProFound AI Risk uniquely combines a range of risk factors, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models1,2.  

-    To download the software user guide, click here.
-    To request an in-person training session with company representatives, click here.
-    To receive examples of clinical case processing or SW demonstration, click here. 
-    To request a pilot use, click here.